drugs with tirzepatide Associated Lower POAG, OHT Risk Compared with Other GLP-1 March 10, 2025: Patients transitioning

The compounded version of semaglutide, however, is not FDA approved

Regular screening may be done if you have risk factors or symptoms such as fatigue, numbness, or pale skin

Their impact may extend far beyond the obesity market, opening billion-dollar side markets

These innovative shots have gained popularity among individuals seeking effective ways to shed pounds and boost their overall health

To view or add a comment, sign in New Clinical Trial: Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter Intra-Abdominal Hypertension | Phase: N/A | Sponsor: Wake Forest University Health Sciences | The purpose of this study is to investigate the intra-abdominal pressure utilizing the Accuryn monitoring system during pulsed field ablation procedures in the electrophysiology lab compared to the ty #clinicaltrials #healthcare #research #clinicalmetric To view or add a comment, sign in Ahead of Lp(a) Awareness Day , there was a great discussion published in the journal of clinical lipidology, about Lp(a) JCL roundtable: European perspective on comprehensive lipid management and cardiovascular health Lp(a) is a genetic risk factor that should be tested for in all adults, and used to inform overall risk assessment and treatment intensity